Navigation Links
MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
Date:9/19/2007

FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO Surgical Corp. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

All of the offered shares will be sold by MAKO Surgical Corp. The number of shares to be offered and the price range of the offering have not yet been determined. The Company intends to apply to have its common stock approved for quotation on the NASDAQ Global Market under the symbol "MAKO."

J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will act as joint bookrunners for the offering and Cowen and Company, LLC and Wachovia Capital Markets, LLC will act as co-lead managers. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its advanced robotic solution and implants for minimally invasive orthopedic knee procedures. MAKO's Haptic Guidance System(TM) includes an interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of resurfacing implants through a keyhole incision. This FDA-cleared surgeon- interactive haptic robotic system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. As of September 18, 2007, 80 MAKOplasty procedures have been performed since commercial introduction in June 2006. MAKO has an intellectual property portfolio of more than two hundred licensed or owned patent applications relating to the areas of computer assisted surgery, haptics, robotics, and implants.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


'/>"/>
SOURCE MAKO Surgical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
2. Surgical products company wins Governors Business Plan Contest
3. Vector Surgical hopes to turn frustration into faster surgeries
4. Metavante Corp. will continue M&A activity
5. Lucigen Corp. enters global licensing agreement
6. CIO Leadership Series: Jane Durment, Marcus Corp.
7. Brady Corp. acquires Korean counterpart
8. Brady Corp. raises $137 million in public offering
9. Symphony Corp. and CareEvolution to partner
10. RedPrairie Corp. introduces new supply chain software
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):